内科

目的探讨齐拉西酮联合脑电生物反馈治疗慢性精神分裂症的临床效果。方法将110例慢性精神分裂症患者随机分为齐拉西酮联合脑电生物反馈组55例（研究组，实际完成53例）和齐拉西酮组55例（对照组，实际完成 52例）。两组患者在精神科常规护理基础上，对照组给予齐拉西酮治疗，研究组给予齐拉西酮联合脑电生物反馈治疗，疗程8周。采用简明精神病量表（BPRS）、护士用住院精神病人观察量表（NOSIE-30）对疗效进行评定。结果第8周末研究组患者BPRS总分低于对照组（t=3.982，P=0.000）；研究组在第4、6周末的治疗总有效率均显著高于对照组，比较差异有统计学意义（P＜0.05）。在第8周末，两组患者的NOSIE总分、总积极因素分、总消极因素分及各因子分（除外社会兴趣、个人整洁因子外）比较差异有统计学意义（P＜0.01或P＜0.05）。结论齐拉西酮联合脑电生物反馈治疗慢性精神分裂症，其疗效和对行为障碍的改善程度均优于单用齐拉西酮治疗。

ObjectiveTo investigate the efficacy of ziprasidone combined with EEG biofeedback therapy on patients with chronic schizophrenia. Methods110 patients with chronic schizophrenia were randomly divided into ziprasidone combined with EEG biofeedback group(study group with 55 cases, the actual completion of 53 cases) and ziprasidone group (control group with 55 cases, the actual completion of 52 cases).Both groups were given psychiatric routine nursing, and the control group received ziprasidone treatment, while the study group received ziprasidone combined with EEG biofeedback therapy, the course of treatment in two groups were 8 weeks.The brief psychiatric rating scale (BPRS), nurse with psychiatric inpatients observation scale (NOSIE-30) were used to evaluate the efficacy. ResultsAfter treatment for 8 weeks,the total score of BPRS in study group was significantly less than that in control group (t=3.982,P=0.000); the total effective rates of study group were significantly higher than that in control group after treatment for 4 and 6 weeks (P＜0.05). The difference of NOSIE score, total positive factors, and total points of negative factors and factor scores (except the social interest, personal cleanliness factor)between two groups were statistically significant after treatment for 4 and 6 weeks(P＜0.01 or P＜0.05). ConclusionsZiprasidone combined with EEG biofeedback has significant efficacy in treatment of chronic schizophrenia, and can improve the degree of behavioral disorders, which is better than ziprasidone treatment alone.